Morgan Stanley’s Aspire Biopharma ASBP Stock Holding History

Morgan Stanley’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,565	Closed	-$79.3K	–	8664
2026 Q1	$79.3K	Buy	+2,565	New	+$137K	﹤0.01%	6251

Other funds holding ASBP

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return

Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley's ASBP Position: Q2 2026 in Review

Morgan Stanley sold out of Aspire Biopharma (ASBP) in Q2 2026, closing a stake of 2,565 shares — an estimated $79.3K sold.

Morgan Stanley first reported a position in ASBP in Q1 2026 and held it in 1 quarter. The position peaked at $79.3K in Q1 2026. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

Morgan Stanley reported no remaining Aspire Biopharma position as of Q2 2026 after selling out during the quarter.
Morgan Stanley sold 2,565 Aspire Biopharma shares in Q2 2026, an estimated $79.3K.
Morgan Stanley first reported a position in Aspire Biopharma in Q1 2026 and held it in 1 quarter.
Morgan Stanley's Aspire Biopharma position peaked at $79.3K in Q1 2026.
13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.